Imbio Announces $1.5 Million Financing

Imbio, LLC, a medical imaging software company, has closed on $1.5 million in Series A financing. Existing investor Invenshure, LLC, led the round with additional funding from several angel investors. The proceeds will support the commercialization of Imbio’s proprietary Parametric Response Mapping (PRM) technology used to detect, characterize and quantify abnormal tissue in computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) images.

“We appreciate the continued support of our investors as we move closer to launching the first application of our PRM technology, PRM LUNG,” said Troy Kopischke, President and ChiefOperating Officer of Imbio. “PRM LUNG is designed to significantly improve the diagnostic power of CT scans in chronic obstructive pulmonary disease (COPD), a progressive condition that is the third leading cause of death in the U.S.” Danny Cunagin, co-founder of Invenshure, commented, “We are pleased to support this break through technology. PRM LUNG has the potential to be the first imaging software to distinguish between the sub-types of COPD, helping physicians personalize treatment for patients.”

About Imbio, LLC
Imbio, LLC, is a medical imaging company founded to commercialize quantitative imaging biomarkers developed by leading universities and research institutions. Imaging biomarkers are key drivers of personalized medicine, which is rapidly evolving due to “big data” availability in cloud databases. Imbio is developing and licensing several imaging biomarkers that will be added to the company’s growing imaging/processing cloud platform. For more information, visit

About Invenshure, LLC
Formed in 2011 by seasoned serial entrepreneurs Danny Cunagin and Troy Kopischke, Invenshure combines a technology incubator (Invenshure, LLC) and a fund (Invenshure Fund I) to launch and grow technology based companies. The principals at Invenshure search industry and universities, commercializing novel medical informatics, therapeutic and platform technologies in the rapidly evolving healthcare marketplace. Find out more at